<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02638948</url>
  </required_header>
  <id_info>
    <org_study_id>IM006-016</org_study_id>
    <secondary_id>2015-002887-17</secondary_id>
    <nct_id>NCT02638948</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of BMS-986142 in Patients With Moderate to Severe Rheumatoid Arthritis</brief_title>
  <official_title>Phase 2, Randomized, Multi-Center, Double-Blind, Dose-Ranging, Placebo Controlled, Adaptive Design Study to Evaluate the Efficacy and Safety/Pharmacokinetics of BMS-986142 in Subjects With Moderate to Severe Rheumatoid Arthritis With an Inadequate Response to Methotrexate With or Without TNF Inhibitors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether the study drug, BMS-986142, is safe and
      effective in treating moderate to severe rheumatoid arthritis in subjects with an inadequate
      response to methotrexate or methotrexate and up to 2 tumour necrosis factor (TNF) Inhibitors.
      Patients who qualify will be randomized to either one of 3 doses of BMS-986142 or placebo in
      1:1:1 randomization for 12 weeks. Disease activity and safety will be assessed over the
      course of the study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 16, 2016</start_date>
  <completion_date type="Actual">May 3, 2018</completion_date>
  <primary_completion_date type="Actual">May 3, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>ACR responses are assessed with a composite rating scale of the American College of Rheumatology that includes 7 variables: tender joint count (TJC); swollen joint count (SJC); levels of an acute phase reactant C-reactive Protein levels (CRP); participant's assessment of pain; participant's global assessment of disease activity; physician's global assessment of disease activity; participant's assessment of physical function by health assessment questionnaire disability index (HAQ-DI). ACR20 is defined as achieving at least 20% improvement in both TJC and SJC, and at least 20% improvement in at least 3 of the 5 other assessments of the ACR. Percentage of Participants achieving ACR20 = (number of participants with measure/event of interest)/(number of particpants in the analysis)*100</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>ACR responses are assessed with a composite rating scale of the American College of Rheumatology that includes 7 variables: TJC; SJC; levels of an acute phase reactant (CRP level); participant's assessment of pain; participant's global assessment of disease activity; physician's global assessment of disease activity; participant's assessment of physical function by HAQ--DI. ACR70 is defined as achieving at least 70% improvement in both TJC and SJC, and at least 70% improvement in at least 3 of the 5 other assessments of the ACR. Percentage of Participants achieving ACR70 = (number of participants with measure/event of interest)/(number of particpants in the analysis)*100</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 20% Response Over Time From Baseline to Week 12</measure>
    <time_frame>Baseline, Day 15, Day 29, Day 57, Day 85</time_frame>
    <description>ACR responses are assessed with a composite rating scale of the American College of Rheumatology that includes 7 variables: tender joint count (TJC); swollen joint count (SJC); levels of an acute phase reactant C-reactive Protein levels (CRP); participant's assessment of pain; participant's global assessment of disease activity; physician's global assessment of disease activity; participant's assessment of physical function by health assessment questionnaire disability index (HAQ-DI). ACR20 is defined as achieving at least 20% improvement in both TJC and SJC, and at least 20% improvement in at least 3 of the 5 other assessments of the ACR. Percentage of Participants achieving ACR20 = (number of participants with measure/event of interest)/(number of particpants in the analysis)*100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response Over Time From Baseline to Week 12</measure>
    <time_frame>Baseline, Day 15, Day 29, Day 57, Day 85</time_frame>
    <description>ACR responses are assessed with a composite rating scale of the American College of Rheumatology that includes 7 variables: TJC; SJC; levels of an acute phase reactant (CRP level); participant's assessment of pain; participant's global assessment of disease activity; physician's global assessment of disease activity; participant's assessment of physical function by HAQ--DI. ACR70 is defined as achieving at least 50% improvement in both TJC and SJC, and at least 50% improvement in at least 3 of the 5 other assessments of the ACR. Percentage of Participants achieving ACR50 = (number of participants with measure/event of interest)/(number of particpants in the analysis)*100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving American College of Rheumatology 70% Response Over Time From Baseline to Week 12</measure>
    <time_frame>Baseline, Day 15, Day 29, Day 57, Day 85</time_frame>
    <description>ACR responses are assessed with a composite rating scale of the American College of Rheumatology that includes 7 variables: TJC; SJC; levels of an acute phase reactant (CRP level); participant's assessment of pain; participant's global assessment of disease activity; physician's global assessment of disease activity; participant's assessment of physical function by HAQ--DI. ACR70 is defined as achieving at least 70% improvement in both TJC and SJC, and at least 70% improvement in at least 3 of the 5 other assessments of the ACR. Percentage of Participants achieving ACR70 = (number of participants with measure/event of interest)/(number of particpants in the analysis)*100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving &lt; 2.6 Response in Disease Activity Score for 28 Joints -C-Reactive Protein (DAS28--CRP) Score at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>DAS28 is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); General health (GH) assessment by the participant assessed from the ACR rheumatoid arthritis (RA) core set questionnaire (participant global assessment) in 100 mm visual analog scale (VAS). Marker of inflammation assessed by the high sensitivity C-reactive protein (hs-CRP) in mg/L. The DAS28 score provides a number indicating the current disease activity of the RA. DAS28 total score ranges from 2-10. A DAS28 score above 5.1 means high disease activity, whereas a DAS28 score below 3.2 indicates low disease activity and a DAS28 score below 2.6 means disease remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving &lt; 2.6 Response in Disease Activity Score for 28 Joints Erythrocyte Sedimentation Rate (DAS28--ESR) Score at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>DAS28-ESR is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); General health (GH) assessment by the participant assessed from the ACR RA core set questionnaire (participant global assessment) in 100 mm VAS; Marker of inflammation assessed by ESR in mm/hr. The DAS28-ESR score provides a number indicating the current disease activity of the RA. DAS28-ESR total score ranges from 2-10. A DAS28-ESR score above 5.1 means high disease activity, DAS28-ESR score below 3.2 indicates low disease activity and DAS28-ESR score below 2.6 means disease remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving &lt;= 2.8 Response in Clinical Disease Activity Index (CDAI) Score at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>CDAI is a composite index constructed to measure clinical remission in RA that does not include a laboratory test, and is a numerical summation of 4 components: TJC (28 joints), SJC (28 joints), Participant's Global Assessment of Disease Activity VAS (in cm), and Physician's Global Assessment of Disease VAS (in cm). Total scores ranges from 0 to 76 with a negative change in CDAI score indicating an improvement in disease activity and a positive change in score indicating a worsening of disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving &lt;= 3.3 Response in Simple Disease Activity Index (SDAI) Score at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, patient global assessment (PtGA) and physician global assessment (PGA) assessed on a VAS scale ranging from 0 to 10 cm, where higher scores indicate greater affection due to disease activity, and CRP measured in terms of milligram per deciliter (mg/dL). SDAI total score ranges from 0 to 86. SDAI &lt;= 3.3 indicates disease remission, &gt; 3.4 to 11 indicates low disease activity, &gt;11 to 26 indicates moderate disease activity, and &gt;26 indicates high disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants Achieving Boolean Remission Criteria at Week 12</measure>
    <time_frame>Week 12</time_frame>
    <description>Boolean remission criteria was defined as: tender joint count28 &lt;= 1; swollen joint count28 &lt;= 1; physician's global assessment &lt;= 1; and CRP &lt;= 1 mg/deciliter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DAS28-CRP Score Over Time up to Week 12</measure>
    <time_frame>Baseline, Day 85 (Week 12)</time_frame>
    <description>DAS28 is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); General health (GH) assessment by the participant assessed from the ACR rheumatoid arthritis (RA) core set questionnaire (participant global assessment) in 100 mm visual analog scale (VAS). Marker of inflammation assessed by the high sensitivity C-reactive protein (hs-CRP) in mg/L. The DAS28 score provides a number indicating the current disease activity of the RA. DAS28 total score ranges from 2-10. A DAS28 score above 5.1 means high disease activity, whereas a DAS28 score below 3.2 indicates low disease activity and a DAS28 score below 2.6 means disease remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in DAS28-ESR Score Over Time up to Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>DAS28-ESR is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); General health (GH) assessment by the participant assessed from the ACR RA core set questionnaire (participant global assessment) in 100 mm VAS; Marker of inflammation assessed by ESR in mm/hr. The DAS28-ESR score provides a number indicating the current disease activity of the RA. DAS28-ESR total score ranges from 2-10. A DAS28-ESR score above 5.1 means high disease activity, DAS28-ESR score below 3.2 indicates low disease activity and DAS28-ESR score below 2.6 means disease remission.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in CDAI Score Over Time up to Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>CDAI is a composite index constructed to measure clinical remission in RA that does not include a laboratory test, and is a numerical summation of 4 components: TJC (28 joints), SJC (28 joints), Participant's Global Assessment of Disease Activity VAS (in cm), and Physician's Global Assessment of Disease VAS (in cm). Total scores ranges from 0 to 76 with a negative change in CDAI score indicating an improvement in disease activity and a positive change in score indicating a worsening of disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in SDAI Score Over Time up to Week 12</measure>
    <time_frame>Baseline, Week 12</time_frame>
    <description>The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, PtGA and PGA assessed on a VAS scale ranging from 0 to 10 cm, where higher scores indicate greater affection due to disease activity, and CRP measured in terms of mg/dL. SDAI total score ranges from 0 to 86. SDAI &lt;= 3.3 indicates disease remission, &gt; 3.4 to 11 indicates low disease activity, &gt;11 to 26 indicates moderate disease activity, and &gt;26 indicates high disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AEs), and Serious AEs (SAEs)</measure>
    <time_frame>Up to 30 days after treatment discontinuation</time_frame>
    <description>An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability/incapacity, or a congenital anomaly, or a medically important event.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough Observed Plasma Concentration (Ctrough) of BMS-986142</measure>
    <time_frame>Week 4, 8, and 12</time_frame>
    <description>Ctrough was defined as trough observed plasma concentration.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Scores for Synovitis at Week 4 and 12</measure>
    <time_frame>Week 4 and Week 12</time_frame>
    <description>Synovitis is assessed in 3 wrist regions (A. the distal radioulnar joint; B. the radiocarpal joint; C. the intercarpal and carpometacarpophalangeal, CMC, joints) and in each MCP joint. For each wrist region, possible score ranges from 0-3, with 0=normal, 1=mild, 2=moderate, and 3=severe damage. The total synovitis score per wrist=the sum of the individual scores for the 3 wrist regions. Minimum score per wrist ranges from 0, indicating no damage, to 9 (score of 3*3 wrist regions), indicating most severe damage. A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Scores for Osteitis at Week 4 and 12</measure>
    <time_frame>Week 4, and Week 12</time_frame>
    <description>Osteitis was assessed at a total of 23 anatomic locations: 15 in 1 wrist and 8 in the hand of the same side. Each site is scored in 1.0 increments from 0 to 3, indicating involvement of original articular bone. The total score for the hands/wrists is the sum of the individual scores for each location. Thus the maximum score achievable per hand/wrist is 23 (total number of anatomic locations) * 3 (maximum per joint)=69. Minimum score=0, indicating normal. Increasing score=greater severity. A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Scores for Bone Erosion at Week 4 and 12</measure>
    <time_frame>Week 4 and Week 12</time_frame>
    <description>Bone erosion assessed at a total of 23 anatomic locations: 15 in 1 wrist and 8 in the hand of the same side. Each site is scored in 1.0 increments from 0 (no damage) to 10 (severe damage) according to erosion of the original articular bone (each unit=10% loss of articular bone). The total erosion score for the hands/wrists is the sum of the individual scores for each location. Thus the maximum score achievable per hand/wrist is 230. Increasing score=greater severity.A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change From Baseline in Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Scores for Cartilage Loss at Week 4 and 12</measure>
    <time_frame>Week 4, and Week12</time_frame>
    <description>Cartilage loss was assessed by MRI. Scans of 25 joints were read and scored for each participant by assessors. Scores for each location ranged 0-4 on a 9-point scale, with 0= no cartilage loss and 4= complete cartilage loss. Total score was the sum of the 25 individual scores and ranged 0-100 with 0= no cartilage loss and 100= most severe cartilage loss. A negative change from baseline indicates improvement.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">508</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo + Methotrexate dose as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986142 at dose level 1+ Methotrexate as specified</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986142 at dose level 2 + Methotrexate as specified</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986142</intervention_name>
    <description>BMS986142 specific dose on specific days</description>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo of BMS-986142 specific dose on specific days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>Methotrexate specific dose on specific days</description>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Male and female age 18 and above

          -  Diagnosed with active rheumatoid arthritis (RA) by standard criteria at least 16 weeks
             before screening, have functional ACR class I-III

          -  Have an inadequate response to methotrexate

          -  In addition to an inadequate response to methotrexate have an inadequate response or
             intolerance to 1 but not more than 2 TNF inhibitors

          -  Have a minimum of 6 swollen and 6 tender joints (from 66/68 joint count)

          -  Have hsCRP of ≥ 0.8 mg/dL (8mg/L) [by central laboratory values] or an ESR ≥ 28 mm/hr

          -  Willing to use effective birth control for the entire length of the study

        Exclusion Criteria:

          -  Diagnosed with juvenile Rheumatoid Arthritis

          -  Have been treated with other biologic treatment than a TNF inhibitor

          -  Active systemic bacterial, viral or fungal infection or evidence of prior or current
             Hepatitis B or C infection or HIV infection, latent bacterial, viral or fungal
             infections

          -  Have been treated with Intramuscular or Intra-articular glucocorticosteroids within 4
             weeks of randomization

          -  Taking Oral steroids at dose above 10 mg/day of prednisone (or prednisone equivalents)

          -  Have other autoimmune disease other than RA like lupus, multiple sclerosis

          -  Have significant concurrent medical condition at the time of screening or baseline
             visit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>120 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rheumatology Associates Of North Alabama, P.C.</name>
      <address>
        <city>Huntsville</city>
        <state>Alabama</state>
        <zip>35801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Joseph Heritage Medical Group</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>C.V Mehta M.D Medical Corp</name>
      <address>
        <city>Hemet</city>
        <state>California</state>
        <zip>92543</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HCP Clinical Research, LLC</name>
      <address>
        <city>Huntington Beach</city>
        <state>California</state>
        <zip>92646</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Research Organization</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Leon Medical Research</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>San Marcus Research Clinic, Inc.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coral Research Clinic Corp</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Arthritis Center</name>
      <address>
        <city>Palm Harbor</city>
        <state>Florida</state>
        <zip>34684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vizae Clinical Trials Management</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Integral Rheumatology &amp; Immunology Specialists</name>
      <address>
        <city>Plantation</city>
        <state>Florida</state>
        <zip>33324</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Georgia Rheumatology Group</name>
      <address>
        <city>Lawrenceville</city>
        <state>Georgia</state>
        <zip>30046</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis And Diabetes Clinic</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology Study Group</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aa Mrc Llc</name>
      <address>
        <city>Grand Blanc</city>
        <state>Michigan</state>
        <zip>48439</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albuquerque Center For Rheumatology</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Albuquerque Clinical Trials</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Paramount Medical Research &amp; Consulting, Llc</name>
      <address>
        <city>Middleburg Heights</city>
        <state>Ohio</state>
        <zip>44130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Penn Rheumatology</name>
      <address>
        <city>Bethlehem</city>
        <state>Pennsylvania</state>
        <zip>18015</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altoona Center For Clinical Research</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635-8406</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Rheumatology &amp; Arthritis Research Center, P.C</name>
      <address>
        <city>Wexford</city>
        <state>Pennsylvania</state>
        <zip>15090</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wyomissing</city>
        <state>Pennsylvania</state>
        <zip>19610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Tennessee Research Institute</name>
      <address>
        <city>Jackson</city>
        <state>Tennessee</state>
        <zip>38305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pharma Tex Research</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tekton Research Inc</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Rheumatology Research LLC</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <zip>1015</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aprillus Asistencia e Investigacion</name>
      <address>
        <city>Capital Federal</city>
        <state>Buenos Aires</state>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto De Rehabilitacion Psicofisica</name>
      <address>
        <city>Buenos Aires</city>
        <zip>1428</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Reumatologico Strusberg</name>
      <address>
        <city>Cordoba</city>
        <zip>5000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Fuer Innere Medizin 3</name>
      <address>
        <city>Wien</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Goiania</city>
        <state>Goias</state>
        <zip>74110-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Juiz de Fora</city>
        <state>Minas Gerais</state>
        <zip>36010570</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Curitiba</city>
        <state>Parana</state>
        <zip>80030-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Porto Alegre</city>
        <state>RIO Grande DO SUL</state>
        <zip>90035-903</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Porto Alegre</city>
        <state>RIO Grande DO SUL</state>
        <zip>90480-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Santo Andre</city>
        <state>SAO Paulo</state>
        <zip>09190510</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04032-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04266-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Aggarwal And Associates</name>
      <address>
        <city>Brampton</city>
        <state>Ontario</state>
        <zip>L6T 0G1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Anil K Gupta Med Prof Corp</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M9V 4B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Corbeil Essonnes</city>
        <zip>91100</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montpellier Cedex 5</city>
        <zip>34295</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Orleans cedex 2</city>
        <zip>45067</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Strasbourg Cedex</city>
        <zip>67098</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asklepios Gesundheitszentrum</name>
      <address>
        <city>Elmshorn</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinsche Universitaetsklinik Freiburg</name>
      <address>
        <city>Freiburg</city>
        <zip>79106</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Smo.Md Gmbh</name>
      <address>
        <city>Magdeburg</city>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nagoya-shi</city>
        <state>Aichi</state>
        <zip>4578511</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Fukuoka-shi</city>
        <state>Fukuoka</state>
        <zip>8108563</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kitakyushu-shi</city>
        <state>Fukuoka</state>
        <zip>8078555</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>0608604</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>0608648</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sapporo-shi</city>
        <state>Hokkaido</state>
        <zip>0630811</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kato-shi</city>
        <state>Hyogo</state>
        <zip>6731462</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sagamihara-shi</city>
        <state>Kanagawa</state>
        <zip>2520392</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kumamoto-shi</city>
        <state>Kumamoto</state>
        <zip>8620976</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sendai-shi</city>
        <state>Miyagi</state>
        <zip>9808574</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Sasebo-shi</city>
        <state>Nagasaki</state>
        <zip>8571195</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kawachinagano</city>
        <state>Osaka</state>
        <zip>5868521</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Osaka-shi</city>
        <state>Osaka</state>
        <zip>5458586</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Iruma-gun</city>
        <state>Saitama</state>
        <zip>3500495</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Kawagoe-shi</city>
        <state>Saitama</state>
        <zip>3508550</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Hamamatsu-shi</city>
        <state>Shizuoka</state>
        <zip>4308558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>1048560</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Itabashi-ku</city>
        <state>Tokyo</state>
        <zip>1738610</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Meguro-ku</city>
        <state>Tokyo</state>
        <zip>1538515</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Shinjuku-Ku</city>
        <state>Tokyo</state>
        <zip>1608582</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Osaki-shi</city>
        <zip>9896183</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Daegu</city>
        <zip>41931</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CINTRE - Centro de investigacion y tratamiento reumatologico, S.C.</name>
      <address>
        <city>Mexico City</city>
        <state>Distrito Fededral</state>
        <zip>11850</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultorio Privado de Especialidad</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>42650</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica de Investigacion en Reumatologia y Obesidad S.C.</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44650</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo LEON</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Villahermosa</city>
        <state>Tabasco</state>
        <zip>86190</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unidad Reumatologica Las Americas, S.C. P.</name>
      <address>
        <city>Merida</city>
        <state>Yucatan</state>
        <zip>97000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Alta Especialidad en Reumatologia e Investigacion del Potosi S.C.</name>
      <address>
        <city>Distrito Federal</city>
        <zip>03100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Maasstad Ziekenhuis Rotterdam</name>
      <address>
        <city>Rotterdam</city>
        <zip>3079 DZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nzoz Osteo-Medic S.C. A. Racewicz, J.Supronik</name>
      <address>
        <city>Bialystok</city>
        <zip>15-351</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bialystok</city>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Badan Klinicznych JCI Life Science Park</name>
      <address>
        <city>Krakow</city>
        <zip>30-348</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lublin</city>
        <zip>20-954</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nadarzyn</city>
        <zip>05-830</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Poznan</city>
        <zip>60-218</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Warszawa</city>
        <zip>00-465</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji</name>
      <address>
        <city>Warszawa</city>
        <zip>02-637</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Warszawa</city>
        <zip>02-691</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moscow</city>
        <zip>119049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Moscow</city>
        <zip>121374</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194356</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>St Petersburg</city>
        <zip>191124</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Tolyatti</city>
        <zip>445039</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Benoni</city>
        <state>Gauteng</state>
        <zip>1500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Cape Town</city>
        <state>Western CAPE</state>
        <zip>7500</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>George</city>
        <state>Western CAPE</state>
        <zip>6529</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Somerset West</city>
        <state>Western CAPE</state>
        <zip>7129</zip>
        <country>South Africa</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>A Coruna</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Santiago Compostela</city>
        <zip>15702</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Taichung</city>
        <zip>402</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Taipei</city>
        <zip>11031</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>South Africa</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Belgium</country>
  </removed_countries>
  <link>
    <url>http://bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_inquiry_form.aspx</url>
    <description>Investigator Inquiry Form</description>
  </link>
  <verification_date>May 2019</verification_date>
  <study_first_submitted>December 21, 2015</study_first_submitted>
  <study_first_submitted_qc>December 21, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2015</study_first_posted>
  <results_first_submitted>May 1, 2019</results_first_submitted>
  <results_first_submitted_qc>May 2, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 28, 2019</results_first_posted>
  <last_update_submitted>May 2, 2019</last_update_submitted>
  <last_update_submitted_qc>May 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 28, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 29, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT02638948/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 4, 2015</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT02638948/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Out of 508 participants who signed the informed consent form and were enrolled in the study; 248 participants were randomized, and 247 participants were administered study drug (1 participant did not take any double-blind study medication).</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>Oral dose of matching placebo for BMS-986142 was administered daily for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>BMS 100mg</title>
          <description>Oral dose of BMS-986142 100mg was administered daily for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>BMS 200mg</title>
          <description>Oral dose of BMS-986142 200mg was administered daily for 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>BMS 350mg</title>
          <description>Oral dose of BMS-986142 350mg was administered daily for 12 weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="75"/>
                <participants group_id="P2" count="73"/>
                <participants group_id="P3" count="73"/>
                <participants group_id="P4" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="66"/>
                <participants group_id="P2" count="62"/>
                <participants group_id="P3" count="66"/>
                <participants group_id="P4" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Reason by Sponsor</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Poor/Non-Compliance</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Participant no longer met study criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other than specified above</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>All randomized and treated participants.</population>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>Oral dose of matching placebo for BMS-986142 was administered daily for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>BMS 100mg</title>
          <description>Oral dose of BMS-986142 100mg was administered daily for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>BMS 200mg</title>
          <description>Oral dose of BMS-986142 200mg was administered daily for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>BMS 350mg</title>
          <description>Oral dose of BMS-986142 350mg was administered daily for 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="75"/>
            <count group_id="B2" value="73"/>
            <count group_id="B3" value="73"/>
            <count group_id="B4" value="26"/>
            <count group_id="B5" value="247"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58.6" spread="11.61"/>
                    <measurement group_id="B2" value="57.6" spread="13.01"/>
                    <measurement group_id="B3" value="55.2" spread="13.13"/>
                    <measurement group_id="B4" value="52.9" spread="13.16"/>
                    <measurement group_id="B5" value="56.7" spread="12.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="62"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="214"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="84"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="52"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="58"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="188"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="5"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="21"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="31"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Other</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12</title>
        <description>ACR responses are assessed with a composite rating scale of the American College of Rheumatology that includes 7 variables: tender joint count (TJC); swollen joint count (SJC); levels of an acute phase reactant C-reactive Protein levels (CRP); participant's assessment of pain; participant's global assessment of disease activity; physician's global assessment of disease activity; participant's assessment of physical function by health assessment questionnaire disability index (HAQ-DI). ACR20 is defined as achieving at least 20% improvement in both TJC and SJC, and at least 20% improvement in at least 3 of the 5 other assessments of the ACR. Percentage of Participants achieving ACR20 = (number of participants with measure/event of interest)/(number of particpants in the analysis)*100</description>
        <time_frame>Week 12</time_frame>
        <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA).</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral dose of matching placebo for BMS-986142 was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BMS 100mg</title>
            <description>Oral dose of BMS-986142 100mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BMS 200mg</title>
            <description>Oral dose of BMS-986142 200mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BMS 350mg</title>
            <description>Oral dose of BMS-986142 350mg was administered daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 20% (ACR20) Response at Week 12</title>
          <description>ACR responses are assessed with a composite rating scale of the American College of Rheumatology that includes 7 variables: tender joint count (TJC); swollen joint count (SJC); levels of an acute phase reactant C-reactive Protein levels (CRP); participant's assessment of pain; participant's global assessment of disease activity; physician's global assessment of disease activity; participant's assessment of physical function by health assessment questionnaire disability index (HAQ-DI). ACR20 is defined as achieving at least 20% improvement in both TJC and SJC, and at least 20% improvement in at least 3 of the 5 other assessments of the ACR. Percentage of Participants achieving ACR20 = (number of participants with measure/event of interest)/(number of particpants in the analysis)*100</description>
          <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA).</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.7" lower_limit="20.2" upper_limit="41.1"/>
                    <measurement group_id="O2" value="35.6" lower_limit="24.6" upper_limit="46.6"/>
                    <measurement group_id="O3" value="42.5" lower_limit="31.1" upper_limit="53.8"/>
                    <measurement group_id="O4" value="30.8" lower_limit="13.0" upper_limit="48.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.5224</p_value>
            <p_value_desc>Threshold for significance = 0.05</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Estimate of Difference (%)</param_type>
            <param_value>4.9</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.2</ci_lower_limit>
            <ci_upper_limit>20.1</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.1360</p_value>
            <p_value_desc>Threshold for significance = 0.05</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Estimate of Difference (%)</param_type>
            <param_value>11.8</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-3.6</ci_lower_limit>
            <ci_upper_limit>27.2</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.9922</p_value>
            <p_value_desc>Threshold for significance = 0.05</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Estimate of Difference (%)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-20.5</ci_lower_limit>
            <ci_upper_limit>20.7</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Week 12</title>
        <description>ACR responses are assessed with a composite rating scale of the American College of Rheumatology that includes 7 variables: TJC; SJC; levels of an acute phase reactant (CRP level); participant's assessment of pain; participant's global assessment of disease activity; physician's global assessment of disease activity; participant's assessment of physical function by HAQ--DI. ACR70 is defined as achieving at least 70% improvement in both TJC and SJC, and at least 70% improvement in at least 3 of the 5 other assessments of the ACR. Percentage of Participants achieving ACR70 = (number of participants with measure/event of interest)/(number of particpants in the analysis)*100</description>
        <time_frame>Week 12</time_frame>
        <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral dose of matching placebo for BMS-986142 was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BMS 100mg</title>
            <description>Oral dose of BMS-986142 100mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BMS 200mg</title>
            <description>Oral dose of BMS-986142 200mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BMS 350mg</title>
            <description>Oral dose of BMS-986142 350mg was administered daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 70% (ACR70) Response at Week 12</title>
          <description>ACR responses are assessed with a composite rating scale of the American College of Rheumatology that includes 7 variables: TJC; SJC; levels of an acute phase reactant (CRP level); participant's assessment of pain; participant's global assessment of disease activity; physician's global assessment of disease activity; participant's assessment of physical function by HAQ--DI. ACR70 is defined as achieving at least 70% improvement in both TJC and SJC, and at least 70% improvement in at least 3 of the 5 other assessments of the ACR. Percentage of Participants achieving ACR70 = (number of participants with measure/event of interest)/(number of particpants in the analysis)*100</description>
          <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA)</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="0.8" upper_limit="11.2"/>
                    <measurement group_id="O2" value="4.1" lower_limit="0.9" upper_limit="11.5"/>
                    <measurement group_id="O3" value="9.6" lower_limit="2.8" upper_limit="16.3"/>
                    <measurement group_id="O4" value="3.8" lower_limit="0.1" upper_limit="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0000</p_value>
            <p_value_desc>Threshold for significance = 0.05</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Estimate of Difference (%)</param_type>
            <param_value>0.1</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-16.0</ci_lower_limit>
            <ci_upper_limit>16.5</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.2058</p_value>
            <p_value_desc>Threshold for significance = 0.05</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Estimate of Difference (%)</param_type>
            <param_value>5.6</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.5</ci_lower_limit>
            <ci_upper_limit>21.9</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O4</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>1.0000</p_value>
            <p_value_desc>Threshold for significance = 0.05</p_value_desc>
            <method>Chi-squared</method>
            <param_type>Estimate of Difference (%)</param_type>
            <param_value>-0.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-22.5</ci_lower_limit>
            <ci_upper_limit>22.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 20% Response Over Time From Baseline to Week 12</title>
        <description>ACR responses are assessed with a composite rating scale of the American College of Rheumatology that includes 7 variables: tender joint count (TJC); swollen joint count (SJC); levels of an acute phase reactant C-reactive Protein levels (CRP); participant's assessment of pain; participant's global assessment of disease activity; physician's global assessment of disease activity; participant's assessment of physical function by health assessment questionnaire disability index (HAQ-DI). ACR20 is defined as achieving at least 20% improvement in both TJC and SJC, and at least 20% improvement in at least 3 of the 5 other assessments of the ACR. Percentage of Participants achieving ACR20 = (number of participants with measure/event of interest)/(number of particpants in the analysis)*100</description>
        <time_frame>Baseline, Day 15, Day 29, Day 57, Day 85</time_frame>
        <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral dose of matching placebo for BMS-986142 was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BMS 100mg</title>
            <description>Oral dose of BMS-986142 100mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BMS 200mg</title>
            <description>Oral dose of BMS-986142 200mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BMS 350mg</title>
            <description>Oral dose of BMS-986142 350mg was administered daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 20% Response Over Time From Baseline to Week 12</title>
          <description>ACR responses are assessed with a composite rating scale of the American College of Rheumatology that includes 7 variables: tender joint count (TJC); swollen joint count (SJC); levels of an acute phase reactant C-reactive Protein levels (CRP); participant's assessment of pain; participant's global assessment of disease activity; physician's global assessment of disease activity; participant's assessment of physical function by health assessment questionnaire disability index (HAQ-DI). ACR20 is defined as achieving at least 20% improvement in both TJC and SJC, and at least 20% improvement in at least 3 of the 5 other assessments of the ACR. Percentage of Participants achieving ACR20 = (number of participants with measure/event of interest)/(number of particpants in the analysis)*100</description>
          <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA)</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="NA" upper_limit="NA">Here 'NA' signifies not estimable (NE): number of participants with ACR20% response was zero due to which 95% confidence interval was NE</measurement>
                    <measurement group_id="O2" value="0.0" lower_limit="NA" upper_limit="NA">Here 'NA' signifies not estimable (NE): number of participants with ACR20% response was zero due to which 95% confidence interval was NE</measurement>
                    <measurement group_id="O3" value="0.0" lower_limit="NA" upper_limit="NA">Here 'NA' signifies not estimable (NE): number of participants with ACR20% response was zero due to which 95% confidence interval was NE</measurement>
                    <measurement group_id="O4" value="0.0" lower_limit="NA" upper_limit="NA">Here 'NA' signifies not estimable (NE): number of participants with ACR20% response was zero due to which 95% confidence interval was NE</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" lower_limit="3.7" upper_limit="17.7"/>
                    <measurement group_id="O2" value="13.7" lower_limit="5.8" upper_limit="21.6"/>
                    <measurement group_id="O3" value="24.7" lower_limit="14.8" upper_limit="34.5"/>
                    <measurement group_id="O4" value="15.4" lower_limit="4.4" upper_limit="34.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.7" lower_limit="9.8" upper_limit="27.5"/>
                    <measurement group_id="O2" value="23.3" lower_limit="13.6" upper_limit="33.0"/>
                    <measurement group_id="O3" value="21.9" lower_limit="12.4" upper_limit="31.4"/>
                    <measurement group_id="O4" value="26.9" lower_limit="9.9" upper_limit="44.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.0" lower_limit="17.8" upper_limit="38.2"/>
                    <measurement group_id="O2" value="41.1" lower_limit="29.8" upper_limit="52.4"/>
                    <measurement group_id="O3" value="39.7" lower_limit="28.5" upper_limit="51.0"/>
                    <measurement group_id="O4" value="15.4" lower_limit="4.4" upper_limit="34.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.7" lower_limit="20.2" upper_limit="41.1"/>
                    <measurement group_id="O2" value="35.6" lower_limit="24.6" upper_limit="46.6"/>
                    <measurement group_id="O3" value="42.5" lower_limit="31.1" upper_limit="53.8"/>
                    <measurement group_id="O4" value="30.8" lower_limit="13.0" upper_limit="48.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response Over Time From Baseline to Week 12</title>
        <description>ACR responses are assessed with a composite rating scale of the American College of Rheumatology that includes 7 variables: TJC; SJC; levels of an acute phase reactant (CRP level); participant's assessment of pain; participant's global assessment of disease activity; physician's global assessment of disease activity; participant's assessment of physical function by HAQ--DI. ACR70 is defined as achieving at least 50% improvement in both TJC and SJC, and at least 50% improvement in at least 3 of the 5 other assessments of the ACR. Percentage of Participants achieving ACR50 = (number of participants with measure/event of interest)/(number of particpants in the analysis)*100</description>
        <time_frame>Baseline, Day 15, Day 29, Day 57, Day 85</time_frame>
        <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral dose of matching placebo for BMS-986142 was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BMS 100mg</title>
            <description>Oral dose of BMS-986142 100mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BMS 200mg</title>
            <description>Oral dose of BMS-986142 200mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BMS 350mg</title>
            <description>Oral dose of BMS-986142 350mg was administered daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 50% (ACR50) Response Over Time From Baseline to Week 12</title>
          <description>ACR responses are assessed with a composite rating scale of the American College of Rheumatology that includes 7 variables: TJC; SJC; levels of an acute phase reactant (CRP level); participant's assessment of pain; participant's global assessment of disease activity; physician's global assessment of disease activity; participant's assessment of physical function by HAQ--DI. ACR70 is defined as achieving at least 50% improvement in both TJC and SJC, and at least 50% improvement in at least 3 of the 5 other assessments of the ACR. Percentage of Participants achieving ACR50 = (number of participants with measure/event of interest)/(number of particpants in the analysis)*100</description>
          <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA)</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="NA">Here 'NA' signifies not estimable (NE): number of participants with ACR50% response was zero due to which 95% confidence interval was NE</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="NA">Here 'NA' signifies not estimable (NE): number of participants with ACR50% response was zero due to which 95% confidence interval was NE</measurement>
                    <measurement group_id="O3" value="0" lower_limit="NA" upper_limit="NA">Here 'NA' signifies not estimable (NE): number of participants with ACR50% response was zero due to which 95% confidence interval was NE</measurement>
                    <measurement group_id="O4" value="0" lower_limit="NA" upper_limit="NA">Here 'NA' signifies not estimable (NE): number of participants with ACR50% response was zero due to which 95% confidence interval was NE</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="0.3" upper_limit="9.3"/>
                    <measurement group_id="O2" value="4.1" lower_limit="0.9" upper_limit="11.5"/>
                    <measurement group_id="O3" value="5.5" lower_limit="1.5" upper_limit="13.4"/>
                    <measurement group_id="O4" value="3.8" lower_limit="0.1" upper_limit="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="0.3" upper_limit="9.3"/>
                    <measurement group_id="O2" value="4.1" lower_limit="0.9" upper_limit="11.5"/>
                    <measurement group_id="O3" value="6.8" lower_limit="1.1" upper_limit="12.6"/>
                    <measurement group_id="O4" value="7.7" lower_limit="0.9" upper_limit="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" lower_limit="2.7" upper_limit="15.9"/>
                    <measurement group_id="O2" value="12.3" lower_limit="4.8" upper_limit="19.9"/>
                    <measurement group_id="O3" value="13.7" lower_limit="5.8" upper_limit="21.6"/>
                    <measurement group_id="O4" value="7.7" lower_limit="0.9" upper_limit="25.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.3" lower_limit="2.7" upper_limit="15.9"/>
                    <measurement group_id="O2" value="13.7" lower_limit="5.8" upper_limit="21.6"/>
                    <measurement group_id="O3" value="16.4" lower_limit="7.9" upper_limit="24.9"/>
                    <measurement group_id="O4" value="11.5" lower_limit="2.4" upper_limit="30.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving American College of Rheumatology 70% Response Over Time From Baseline to Week 12</title>
        <description>ACR responses are assessed with a composite rating scale of the American College of Rheumatology that includes 7 variables: TJC; SJC; levels of an acute phase reactant (CRP level); participant's assessment of pain; participant's global assessment of disease activity; physician's global assessment of disease activity; participant's assessment of physical function by HAQ--DI. ACR70 is defined as achieving at least 70% improvement in both TJC and SJC, and at least 70% improvement in at least 3 of the 5 other assessments of the ACR. Percentage of Participants achieving ACR70 = (number of participants with measure/event of interest)/(number of particpants in the analysis)*100</description>
        <time_frame>Baseline, Day 15, Day 29, Day 57, Day 85</time_frame>
        <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral dose of matching placebo for BMS-986142 was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BMS 100mg</title>
            <description>Oral dose of BMS-986142 100mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BMS 200mg</title>
            <description>Oral dose of BMS-986142 200mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BMS 350mg</title>
            <description>Oral dose of BMS-986142 350mg was administered daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving American College of Rheumatology 70% Response Over Time From Baseline to Week 12</title>
          <description>ACR responses are assessed with a composite rating scale of the American College of Rheumatology that includes 7 variables: TJC; SJC; levels of an acute phase reactant (CRP level); participant's assessment of pain; participant's global assessment of disease activity; physician's global assessment of disease activity; participant's assessment of physical function by HAQ--DI. ACR70 is defined as achieving at least 70% improvement in both TJC and SJC, and at least 70% improvement in at least 3 of the 5 other assessments of the ACR. Percentage of Participants achieving ACR70 = (number of participants with measure/event of interest)/(number of particpants in the analysis)*100</description>
          <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA)</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline (Day 1)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="NA" upper_limit="NA">Here 'NA' signifies not estimable (NE): number of participants with ACR70% response was zero due to which 95% confidence interval was NE</measurement>
                    <measurement group_id="O2" value="0" lower_limit="NA" upper_limit="NA">Here 'NA' signifies not estimable (NE): number of participants with ACR70% response was zero due to which 95% confidence interval was NE</measurement>
                    <measurement group_id="O3" value="0" lower_limit="NA" upper_limit="NA">Here 'NA' signifies not estimable (NE): number of participants with ACR70% response was zero due to which 95% confidence interval was NE</measurement>
                    <measurement group_id="O4" value="0" lower_limit="NA" upper_limit="NA">Here 'NA' signifies not estimable (NE): number of participants with ACR70% response was zero due to which 95% confidence interval was NE</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 15</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.0" upper_limit="7.2"/>
                    <measurement group_id="O2" value="0.0" lower_limit="0.0" upper_limit="4.9"/>
                    <measurement group_id="O3" value="1.4" lower_limit="0.0" upper_limit="7.4"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 29</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="NA" upper_limit="NA">Here 'NA' signifies not estimable (NE): number of participants with ACR70% response was zero due to which 95% confidence interval was NE.</measurement>
                    <measurement group_id="O2" value="0.0" lower_limit="NA" upper_limit="NA">Here 'NA' signifies NE: number of participants with ACR70% response was zero due to which 95% confidence interval was NE.</measurement>
                    <measurement group_id="O3" value="0.0" lower_limit="NA" upper_limit="NA">Here 'NA' signifies NE: number of participants with ACR70% response was zero due to which 95% confidence interval was NE.</measurement>
                    <measurement group_id="O4" value="0.0" lower_limit="NA" upper_limit="NA">Here 'NA' signifies NE: number of participants with ACR70% response was zero due to which 95% confidence interval was NE.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 57</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.0" upper_limit="7.2"/>
                    <measurement group_id="O2" value="5.5" lower_limit="1.5" upper_limit="13.4"/>
                    <measurement group_id="O3" value="5.5" lower_limit="1.5" upper_limit="13.4"/>
                    <measurement group_id="O4" value="3.8" lower_limit="0.1" upper_limit="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.0" lower_limit="0.8" upper_limit="11.2"/>
                    <measurement group_id="O2" value="4.1" lower_limit="0.9" upper_limit="11.5"/>
                    <measurement group_id="O3" value="9.6" lower_limit="2.8" upper_limit="16.3"/>
                    <measurement group_id="O4" value="3.8" lower_limit="0.1" upper_limit="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving &lt; 2.6 Response in Disease Activity Score for 28 Joints -C-Reactive Protein (DAS28--CRP) Score at Week 12</title>
        <description>DAS28 is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); General health (GH) assessment by the participant assessed from the ACR rheumatoid arthritis (RA) core set questionnaire (participant global assessment) in 100 mm visual analog scale (VAS). Marker of inflammation assessed by the high sensitivity C-reactive protein (hs-CRP) in mg/L. The DAS28 score provides a number indicating the current disease activity of the RA. DAS28 total score ranges from 2-10. A DAS28 score above 5.1 means high disease activity, whereas a DAS28 score below 3.2 indicates low disease activity and a DAS28 score below 2.6 means disease remission.</description>
        <time_frame>Week 12</time_frame>
        <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral dose of matching placebo for BMS-986142 was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BMS 100mg</title>
            <description>Oral dose of BMS-986142 100mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BMS 200mg</title>
            <description>Oral dose of BMS-986142 200mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BMS 350mg</title>
            <description>Oral dose of BMS-986142 350mg was administered daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving &lt; 2.6 Response in Disease Activity Score for 28 Joints -C-Reactive Protein (DAS28--CRP) Score at Week 12</title>
          <description>DAS28 is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); General health (GH) assessment by the participant assessed from the ACR rheumatoid arthritis (RA) core set questionnaire (participant global assessment) in 100 mm visual analog scale (VAS). Marker of inflammation assessed by the high sensitivity C-reactive protein (hs-CRP) in mg/L. The DAS28 score provides a number indicating the current disease activity of the RA. DAS28 total score ranges from 2-10. A DAS28 score above 5.1 means high disease activity, whereas a DAS28 score below 3.2 indicates low disease activity and a DAS28 score below 2.6 means disease remission.</description>
          <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA)</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.7" lower_limit="1.0" upper_limit="12.3"/>
                    <measurement group_id="O2" value="9.6" lower_limit="2.8" upper_limit="16.3"/>
                    <measurement group_id="O3" value="11.0" lower_limit="3.8" upper_limit="18.1"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving &lt; 2.6 Response in Disease Activity Score for 28 Joints Erythrocyte Sedimentation Rate (DAS28--ESR) Score at Week 12</title>
        <description>DAS28-ESR is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); General health (GH) assessment by the participant assessed from the ACR RA core set questionnaire (participant global assessment) in 100 mm VAS; Marker of inflammation assessed by ESR in mm/hr. The DAS28-ESR score provides a number indicating the current disease activity of the RA. DAS28-ESR total score ranges from 2-10. A DAS28-ESR score above 5.1 means high disease activity, DAS28-ESR score below 3.2 indicates low disease activity and DAS28-ESR score below 2.6 means disease remission.</description>
        <time_frame>Week 12</time_frame>
        <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral dose of matching placebo for BMS-986142 was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BMS 100mg</title>
            <description>Oral dose of BMS-986142 100mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BMS 200mg</title>
            <description>Oral dose of BMS-986142 200mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BMS 350mg</title>
            <description>Oral dose of BMS-986142 350mg was administered daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving &lt; 2.6 Response in Disease Activity Score for 28 Joints Erythrocyte Sedimentation Rate (DAS28--ESR) Score at Week 12</title>
          <description>DAS28-ESR is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); General health (GH) assessment by the participant assessed from the ACR RA core set questionnaire (participant global assessment) in 100 mm VAS; Marker of inflammation assessed by ESR in mm/hr. The DAS28-ESR score provides a number indicating the current disease activity of the RA. DAS28-ESR total score ranges from 2-10. A DAS28-ESR score above 5.1 means high disease activity, DAS28-ESR score below 3.2 indicates low disease activity and DAS28-ESR score below 2.6 means disease remission.</description>
          <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA)</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="4.8"/>
                    <measurement group_id="O2" value="6.8" lower_limit="1.1" upper_limit="12.6"/>
                    <measurement group_id="O3" value="1.4" lower_limit="0.0" upper_limit="7.4"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving &lt;= 2.8 Response in Clinical Disease Activity Index (CDAI) Score at Week 12</title>
        <description>CDAI is a composite index constructed to measure clinical remission in RA that does not include a laboratory test, and is a numerical summation of 4 components: TJC (28 joints), SJC (28 joints), Participant's Global Assessment of Disease Activity VAS (in cm), and Physician's Global Assessment of Disease VAS (in cm). Total scores ranges from 0 to 76 with a negative change in CDAI score indicating an improvement in disease activity and a positive change in score indicating a worsening of disease activity.</description>
        <time_frame>Week 12</time_frame>
        <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral dose of matching placebo for BMS-986142 was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BMS 100mg</title>
            <description>Oral dose of BMS-986142 100mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BMS 200mg</title>
            <description>Oral dose of BMS-986142 200mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BMS 350mg</title>
            <description>Oral dose of BMS-986142 350mg was administered daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving &lt;= 2.8 Response in Clinical Disease Activity Index (CDAI) Score at Week 12</title>
          <description>CDAI is a composite index constructed to measure clinical remission in RA that does not include a laboratory test, and is a numerical summation of 4 components: TJC (28 joints), SJC (28 joints), Participant's Global Assessment of Disease Activity VAS (in cm), and Physician's Global Assessment of Disease VAS (in cm). Total scores ranges from 0 to 76 with a negative change in CDAI score indicating an improvement in disease activity and a positive change in score indicating a worsening of disease activity.</description>
          <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA)</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="4.8"/>
                    <measurement group_id="O2" value="6.8" lower_limit="1.1" upper_limit="12.6"/>
                    <measurement group_id="O3" value="6.8" lower_limit="1.1" upper_limit="12.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving &lt;= 3.3 Response in Simple Disease Activity Index (SDAI) Score at Week 12</title>
        <description>The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, patient global assessment (PtGA) and physician global assessment (PGA) assessed on a VAS scale ranging from 0 to 10 cm, where higher scores indicate greater affection due to disease activity, and CRP measured in terms of milligram per deciliter (mg/dL). SDAI total score ranges from 0 to 86. SDAI &lt;= 3.3 indicates disease remission, &gt; 3.4 to 11 indicates low disease activity, &gt;11 to 26 indicates moderate disease activity, and &gt;26 indicates high disease activity.</description>
        <time_frame>Week 12</time_frame>
        <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral dose of matching placebo for BMS-986142 was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BMS 100mg</title>
            <description>Oral dose of BMS-986142 100mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BMS 200mg</title>
            <description>Oral dose of BMS-986142 200mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BMS 350mg</title>
            <description>Oral dose of BMS-986142 350mg was administered daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving &lt;= 3.3 Response in Simple Disease Activity Index (SDAI) Score at Week 12</title>
          <description>The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, patient global assessment (PtGA) and physician global assessment (PGA) assessed on a VAS scale ranging from 0 to 10 cm, where higher scores indicate greater affection due to disease activity, and CRP measured in terms of milligram per deciliter (mg/dL). SDAI total score ranges from 0 to 86. SDAI &lt;= 3.3 indicates disease remission, &gt; 3.4 to 11 indicates low disease activity, &gt;11 to 26 indicates moderate disease activity, and &gt;26 indicates high disease activity.</description>
          <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA)</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" lower_limit="0.0" upper_limit="4.8"/>
                    <measurement group_id="O2" value="6.8" lower_limit="1.1" upper_limit="12.6"/>
                    <measurement group_id="O3" value="6.8" lower_limit="1.1" upper_limit="12.6"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Participants Achieving Boolean Remission Criteria at Week 12</title>
        <description>Boolean remission criteria was defined as: tender joint count28 &lt;= 1; swollen joint count28 &lt;= 1; physician's global assessment &lt;= 1; and CRP &lt;= 1 mg/deciliter.</description>
        <time_frame>Week 12</time_frame>
        <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA)</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral dose of matching placebo for BMS-986142 was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BMS 100mg</title>
            <description>Oral dose of BMS-986142 100mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BMS 200mg</title>
            <description>Oral dose of BMS-986142 200mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BMS 350mg</title>
            <description>Oral dose of BMS-986142 350mg was administered daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants Achieving Boolean Remission Criteria at Week 12</title>
          <description>Boolean remission criteria was defined as: tender joint count28 &lt;= 1; swollen joint count28 &lt;= 1; physician's global assessment &lt;= 1; and CRP &lt;= 1 mg/deciliter.</description>
          <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA)</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" lower_limit="0.0" upper_limit="7.2"/>
                    <measurement group_id="O2" value="4.1" lower_limit="0.9" upper_limit="11.5"/>
                    <measurement group_id="O3" value="4.1" lower_limit="0.9" upper_limit="11.5"/>
                    <measurement group_id="O4" value="0.0" lower_limit="0.0" upper_limit="13.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DAS28-CRP Score Over Time up to Week 12</title>
        <description>DAS28 is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); General health (GH) assessment by the participant assessed from the ACR rheumatoid arthritis (RA) core set questionnaire (participant global assessment) in 100 mm visual analog scale (VAS). Marker of inflammation assessed by the high sensitivity C-reactive protein (hs-CRP) in mg/L. The DAS28 score provides a number indicating the current disease activity of the RA. DAS28 total score ranges from 2-10. A DAS28 score above 5.1 means high disease activity, whereas a DAS28 score below 3.2 indicates low disease activity and a DAS28 score below 2.6 means disease remission.</description>
        <time_frame>Baseline, Day 85 (Week 12)</time_frame>
        <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA). Here 'N' signifies number of participants analyzed who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral dose of matching placebo for BMS-986142 was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BMS 100mg</title>
            <description>Oral dose of BMS-986142 100mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BMS 200mg</title>
            <description>Oral dose of BMS-986142 200mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BMS 350mg</title>
            <description>Oral dose of BMS-986142 350mg was administered daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28-CRP Score Over Time up to Week 12</title>
          <description>DAS28 is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); General health (GH) assessment by the participant assessed from the ACR rheumatoid arthritis (RA) core set questionnaire (participant global assessment) in 100 mm visual analog scale (VAS). Marker of inflammation assessed by the high sensitivity C-reactive protein (hs-CRP) in mg/L. The DAS28 score provides a number indicating the current disease activity of the RA. DAS28 total score ranges from 2-10. A DAS28 score above 5.1 means high disease activity, whereas a DAS28 score below 3.2 indicates low disease activity and a DAS28 score below 2.6 means disease remission.</description>
          <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA). Here 'N' signifies number of participants analyzed who were evaluable for this outcome measure.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="0.141"/>
                    <measurement group_id="O2" value="-1.1" spread="0.176"/>
                    <measurement group_id="O3" value="-1.4" spread="0.168"/>
                    <measurement group_id="O4" value="-1.4" spread="0.194"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in DAS28-ESR Score Over Time up to Week 12</title>
        <description>DAS28-ESR is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); General health (GH) assessment by the participant assessed from the ACR RA core set questionnaire (participant global assessment) in 100 mm VAS; Marker of inflammation assessed by ESR in mm/hr. The DAS28-ESR score provides a number indicating the current disease activity of the RA. DAS28-ESR total score ranges from 2-10. A DAS28-ESR score above 5.1 means high disease activity, DAS28-ESR score below 3.2 indicates low disease activity and DAS28-ESR score below 2.6 means disease remission.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA). Here 'N' signifies number of participants analyzed who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral dose of matching placebo for BMS-986142 was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BMS 100mg</title>
            <description>Oral dose of BMS-986142 100mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BMS 200mg</title>
            <description>Oral dose of BMS-986142 200mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BMS 350mg</title>
            <description>Oral dose of BMS-986142 350mg was administered daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in DAS28-ESR Score Over Time up to Week 12</title>
          <description>DAS28-ESR is a composite score that includes 4 variables: TJC (based on 28 joints); SJC (based on 28 joints); General health (GH) assessment by the participant assessed from the ACR RA core set questionnaire (participant global assessment) in 100 mm VAS; Marker of inflammation assessed by ESR in mm/hr. The DAS28-ESR score provides a number indicating the current disease activity of the RA. DAS28-ESR total score ranges from 2-10. A DAS28-ESR score above 5.1 means high disease activity, DAS28-ESR score below 3.2 indicates low disease activity and DAS28-ESR score below 2.6 means disease remission.</description>
          <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA). Here 'N' signifies number of participants analyzed who were evaluable for this outcome measure.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="63"/>
                <count group_id="O3" value="65"/>
                <count group_id="O4" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.1" spread="0.149"/>
                    <measurement group_id="O2" value="-1.1" spread="0.166"/>
                    <measurement group_id="O3" value="-1.4" spread="0.161"/>
                    <measurement group_id="O4" value="-1.5" spread="0.247"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in CDAI Score Over Time up to Week 12</title>
        <description>CDAI is a composite index constructed to measure clinical remission in RA that does not include a laboratory test, and is a numerical summation of 4 components: TJC (28 joints), SJC (28 joints), Participant's Global Assessment of Disease Activity VAS (in cm), and Physician's Global Assessment of Disease VAS (in cm). Total scores ranges from 0 to 76 with a negative change in CDAI score indicating an improvement in disease activity and a positive change in score indicating a worsening of disease activity.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA). Here 'N' signifies number of participants analyzed who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral dose of matching placebo for BMS-986142 was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BMS 100mg</title>
            <description>Oral dose of BMS-986142 100mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BMS 200mg</title>
            <description>Oral dose of BMS-986142 200mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BMS 350mg</title>
            <description>Oral dose of BMS-986142 350mg was administered daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in CDAI Score Over Time up to Week 12</title>
          <description>CDAI is a composite index constructed to measure clinical remission in RA that does not include a laboratory test, and is a numerical summation of 4 components: TJC (28 joints), SJC (28 joints), Participant's Global Assessment of Disease Activity VAS (in cm), and Physician's Global Assessment of Disease VAS (in cm). Total scores ranges from 0 to 76 with a negative change in CDAI score indicating an improvement in disease activity and a positive change in score indicating a worsening of disease activity.</description>
          <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA). Here 'N' signifies number of participants analyzed who were evaluable for this outcome measure.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="65"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="68"/>
                <count group_id="O4" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.9" spread="1.591"/>
                    <measurement group_id="O2" value="-13.6" spread="2.030"/>
                    <measurement group_id="O3" value="-16.0" spread="1.828"/>
                    <measurement group_id="O4" value="-17.6" spread="2.519"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in SDAI Score Over Time up to Week 12</title>
        <description>The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, PtGA and PGA assessed on a VAS scale ranging from 0 to 10 cm, where higher scores indicate greater affection due to disease activity, and CRP measured in terms of mg/dL. SDAI total score ranges from 0 to 86. SDAI &lt;= 3.3 indicates disease remission, &gt; 3.4 to 11 indicates low disease activity, &gt;11 to 26 indicates moderate disease activity, and &gt;26 indicates high disease activity.</description>
        <time_frame>Baseline, Week 12</time_frame>
        <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA). Here 'N' signifies number of participants analyzed who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral dose of matching placebo for BMS-986142 was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BMS 100mg</title>
            <description>Oral dose of BMS-986142 100mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BMS 200mg</title>
            <description>Oral dose of BMS-986142 200mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BMS 350mg</title>
            <description>Oral dose of BMS-986142 350mg was administered daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in SDAI Score Over Time up to Week 12</title>
          <description>The SDAI is the numerical sum of five outcome parameters: TJC and SJC based on a 28-joint assessment, PtGA and PGA assessed on a VAS scale ranging from 0 to 10 cm, where higher scores indicate greater affection due to disease activity, and CRP measured in terms of mg/dL. SDAI total score ranges from 0 to 86. SDAI &lt;= 3.3 indicates disease remission, &gt; 3.4 to 11 indicates low disease activity, &gt;11 to 26 indicates moderate disease activity, and &gt;26 indicates high disease activity.</description>
          <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA). Here 'N' signifies number of participants analyzed who were evaluable for this outcome measure.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="64"/>
                <count group_id="O2" value="61"/>
                <count group_id="O3" value="64"/>
                <count group_id="O4" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-14.8" spread="1.628"/>
                    <measurement group_id="O2" value="-13.9" spread="2.090"/>
                    <measurement group_id="O3" value="-16.6" spread="1.954"/>
                    <measurement group_id="O4" value="-18.9" spread="3.218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AEs), and Serious AEs (SAEs)</title>
        <description>An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability/incapacity, or a congenital anomaly, or a medically important event.</description>
        <time_frame>Up to 30 days after treatment discontinuation</time_frame>
        <population>All treated participants.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral dose of matching placebo for BMS-986142 was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BMS 100mg</title>
            <description>Oral dose of BMS-986142 100mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BMS 200mg</title>
            <description>Oral dose of BMS-986142 200mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BMS 350mg</title>
            <description>Oral dose of BMS-986142 350mg was administered daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AEs), and Serious AEs (SAEs)</title>
          <description>An AE is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An AE can therefore be any unfavorable and unintended sign (example, a clinically significant abnormal laboratory finding), symptom, or disease temporally associated with the use of a drug, whether or not it is considered related to the drug. An SAE is an AE resulting in any of the following outcomes or deemed significant for any other reason: death, initial or prolonged inpatient hospitalization, life-threatening experience (immediate risk of dying), persistent or significant disability/incapacity, or a congenital anomaly, or a medically important event.</description>
          <population>All treated participants.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="36"/>
                    <measurement group_id="O2" value="39"/>
                    <measurement group_id="O3" value="39"/>
                    <measurement group_id="O4" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Trough Observed Plasma Concentration (Ctrough) of BMS-986142</title>
        <description>Ctrough was defined as trough observed plasma concentration.</description>
        <time_frame>Week 4, 8, and 12</time_frame>
        <population>Analysis was performed on pharmacokinetic population which included all participants who received BMS-986142 and had any available concentration-time data.</population>
        <group_list>
          <group group_id="O1">
            <title>BMS 100mg</title>
            <description>Oral dose of BMS-986142 100mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BMS 200mg</title>
            <description>Oral dose of BMS-986142 200mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BMS 350mg</title>
            <description>Oral dose of BMS-986142 350mg was administered daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Trough Observed Plasma Concentration (Ctrough) of BMS-986142</title>
          <description>Ctrough was defined as trough observed plasma concentration.</description>
          <population>Analysis was performed on pharmacokinetic population which included all participants who received BMS-986142 and had any available concentration-time data.</population>
          <units>nanogram/mL</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="73"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="60"/>
                    <count group_id="O2" value="61"/>
                    <count group_id="O3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="47.9" spread="119.0"/>
                    <measurement group_id="O2" value="111.8" spread="101.7"/>
                    <measurement group_id="O3" value="195.9" spread="91.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="54"/>
                    <count group_id="O2" value="60"/>
                    <count group_id="O3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.2" spread="95.3"/>
                    <measurement group_id="O2" value="92.2" spread="124.5"/>
                    <measurement group_id="O3" value="283.0" spread="133.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="55"/>
                    <count group_id="O2" value="52"/>
                    <count group_id="O3" value="13"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.4" spread="123.0"/>
                    <measurement group_id="O2" value="75.6" spread="155.4"/>
                    <measurement group_id="O3" value="169.5" spread="83.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Scores for Synovitis at Week 4 and 12</title>
        <description>Synovitis is assessed in 3 wrist regions (A. the distal radioulnar joint; B. the radiocarpal joint; C. the intercarpal and carpometacarpophalangeal, CMC, joints) and in each MCP joint. For each wrist region, possible score ranges from 0-3, with 0=normal, 1=mild, 2=moderate, and 3=severe damage. The total synovitis score per wrist=the sum of the individual scores for the 3 wrist regions. Minimum score per wrist ranges from 0, indicating no damage, to 9 (score of 3*3 wrist regions), indicating most severe damage. A negative change from baseline indicates improvement.</description>
        <time_frame>Week 4 and Week 12</time_frame>
        <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA). Here number analyzed = number of randomized and treated participants with non-missing value at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral dose of matching placebo for BMS-986142 was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BMS 100mg</title>
            <description>Oral dose of BMS-986142 100mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BMS 200mg</title>
            <description>Oral dose of BMS-986142 200mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BMS 350mg</title>
            <description>Oral dose of BMS-986142 350mg was administered daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Scores for Synovitis at Week 4 and 12</title>
          <description>Synovitis is assessed in 3 wrist regions (A. the distal radioulnar joint; B. the radiocarpal joint; C. the intercarpal and carpometacarpophalangeal, CMC, joints) and in each MCP joint. For each wrist region, possible score ranges from 0-3, with 0=normal, 1=mild, 2=moderate, and 3=severe damage. The total synovitis score per wrist=the sum of the individual scores for the 3 wrist regions. Minimum score per wrist ranges from 0, indicating no damage, to 9 (score of 3*3 wrist regions), indicating most severe damage. A negative change from baseline indicates improvement.</description>
          <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA). Here number analyzed = number of randomized and treated participants with non-missing value at each time point</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.226"/>
                    <measurement group_id="O2" value="-0.2" spread="0.202"/>
                    <measurement group_id="O3" value="0.1" spread="0.182"/>
                    <measurement group_id="O4" value="0.1" spread="0.558"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="68"/>
                    <count group_id="O2" value="66"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="0.467"/>
                    <measurement group_id="O2" value="-0.0" spread="0.315"/>
                    <measurement group_id="O3" value="-0.3" spread="0.263"/>
                    <measurement group_id="O4" value="0.9" spread="1.163"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Scores for Osteitis at Week 4 and 12</title>
        <description>Osteitis was assessed at a total of 23 anatomic locations: 15 in 1 wrist and 8 in the hand of the same side. Each site is scored in 1.0 increments from 0 to 3, indicating involvement of original articular bone. The total score for the hands/wrists is the sum of the individual scores for each location. Thus the maximum score achievable per hand/wrist is 23 (total number of anatomic locations) * 3 (maximum per joint)=69. Minimum score=0, indicating normal. Increasing score=greater severity. A negative change from baseline indicates improvement.</description>
        <time_frame>Week 4, and Week 12</time_frame>
        <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA). Here number analyzed = number of randomized and treated participants with non-missing value at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral dose of matching placebo for BMS-986142 was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BMS 100mg</title>
            <description>Oral dose of BMS-986142 100mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BMS 200mg</title>
            <description>Oral dose of BMS-986142 200mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BMS 350mg</title>
            <description>Oral dose of BMS-986142 350mg was administered daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Scores for Osteitis at Week 4 and 12</title>
          <description>Osteitis was assessed at a total of 23 anatomic locations: 15 in 1 wrist and 8 in the hand of the same side. Each site is scored in 1.0 increments from 0 to 3, indicating involvement of original articular bone. The total score for the hands/wrists is the sum of the individual scores for each location. Thus the maximum score achievable per hand/wrist is 23 (total number of anatomic locations) * 3 (maximum per joint)=69. Minimum score=0, indicating normal. Increasing score=greater severity. A negative change from baseline indicates improvement.</description>
          <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA). Here number analyzed = number of randomized and treated participants with non-missing value at each time point</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.223"/>
                    <measurement group_id="O2" value="0.2" spread="0.262"/>
                    <measurement group_id="O3" value="0.1" spread="0.148"/>
                    <measurement group_id="O4" value="-0.1" spread="0.249"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="64"/>
                    <count group_id="O2" value="65"/>
                    <count group_id="O3" value="69"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.574"/>
                    <measurement group_id="O2" value="0.5" spread="0.451"/>
                    <measurement group_id="O3" value="0.0" spread="0.257"/>
                    <measurement group_id="O4" value="0.2" spread="0.654"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Scores for Bone Erosion at Week 4 and 12</title>
        <description>Bone erosion assessed at a total of 23 anatomic locations: 15 in 1 wrist and 8 in the hand of the same side. Each site is scored in 1.0 increments from 0 (no damage) to 10 (severe damage) according to erosion of the original articular bone (each unit=10% loss of articular bone). The total erosion score for the hands/wrists is the sum of the individual scores for each location. Thus the maximum score achievable per hand/wrist is 230. Increasing score=greater severity.A negative change from baseline indicates improvement.</description>
        <time_frame>Week 4 and Week 12</time_frame>
        <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA). Here number analyzed = number of randomized and treated participants with non-missing value at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral dose of matching placebo for BMS-986142 was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BMS 100mg</title>
            <description>Oral dose of BMS-986142 100mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BMS 200mg</title>
            <description>Oral dose of BMS-986142 200mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BMS 350mg</title>
            <description>Oral dose of BMS-986142 350mg was administered daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Scores for Bone Erosion at Week 4 and 12</title>
          <description>Bone erosion assessed at a total of 23 anatomic locations: 15 in 1 wrist and 8 in the hand of the same side. Each site is scored in 1.0 increments from 0 (no damage) to 10 (severe damage) according to erosion of the original articular bone (each unit=10% loss of articular bone). The total erosion score for the hands/wrists is the sum of the individual scores for each location. Thus the maximum score achievable per hand/wrist is 230. Increasing score=greater severity.A negative change from baseline indicates improvement.</description>
          <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA). Here number analyzed = number of randomized and treated participants with non-missing value at each time point</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.048"/>
                    <measurement group_id="O2" value="0.1" spread="0.089"/>
                    <measurement group_id="O3" value="-0.0" spread="0.036"/>
                    <measurement group_id="O4" value="0.0" spread="0.030"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.048"/>
                    <measurement group_id="O2" value="0.3" spread="0.248"/>
                    <measurement group_id="O3" value="0.0" spread="0.046"/>
                    <measurement group_id="O4" value="0.1" spread="0.072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change From Baseline in Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Scores for Cartilage Loss at Week 4 and 12</title>
        <description>Cartilage loss was assessed by MRI. Scans of 25 joints were read and scored for each participant by assessors. Scores for each location ranged 0-4 on a 9-point scale, with 0= no cartilage loss and 4= complete cartilage loss. Total score was the sum of the 25 individual scores and ranged 0-100 with 0= no cartilage loss and 100= most severe cartilage loss. A negative change from baseline indicates improvement.</description>
        <time_frame>Week 4, and Week12</time_frame>
        <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA). Here number analyzed = number of randomized and treated participants with non-missing value at each time point</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral dose of matching placebo for BMS-986142 was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>BMS 100mg</title>
            <description>Oral dose of BMS-986142 100mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>BMS 200mg</title>
            <description>Oral dose of BMS-986142 200mg was administered daily for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>BMS 350mg</title>
            <description>Oral dose of BMS-986142 350mg was administered daily for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change From Baseline in Rheumatoid Arthritis Magnetic Resonance Imaging Scoring System (RAMRIS) Scores for Cartilage Loss at Week 4 and 12</title>
          <description>Cartilage loss was assessed by MRI. Scans of 25 joints were read and scored for each participant by assessors. Scores for each location ranged 0-4 on a 9-point scale, with 0= no cartilage loss and 4= complete cartilage loss. Total score was the sum of the 25 individual scores and ranged 0-100 with 0= no cartilage loss and 100= most severe cartilage loss. A negative change from baseline indicates improvement.</description>
          <population>Analysis was performed on efficacy population which excluded participants who were randomized to a treatment arm and discontinued based on the interim analysis (IA). Here number analyzed = number of randomized and treated participants with non-missing value at each time point</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="75"/>
                <count group_id="O2" value="73"/>
                <count group_id="O3" value="73"/>
                <count group_id="O4" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 4</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" spread="0.105"/>
                    <measurement group_id="O2" value="0.0" spread="0.064"/>
                    <measurement group_id="O3" value="-0.0" spread="0.079"/>
                    <measurement group_id="O4" value="0.4" spread="0.169"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="69"/>
                    <count group_id="O2" value="67"/>
                    <count group_id="O3" value="70"/>
                    <count group_id="O4" value="23"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="0.116"/>
                    <measurement group_id="O2" value="0.3" spread="0.139"/>
                    <measurement group_id="O3" value="0.0" spread="0.111"/>
                    <measurement group_id="O4" value="0.5" spread="0.294"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All Adverse Events were collected from signature of the informed consent until 30 days after last treatment administration. (Approximately 26 months)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>BMS-986142 100mg</title>
          <description>Oral dose of BMS-986142 100mg was administered daily for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>BMS-986142 200mg</title>
          <description>Oral dose of BMS-986142 200mg was administered daily for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>BMS-986142 350mg</title>
          <description>Oral dose of BMS-986142 350mg was administered daily for 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>Placebo</title>
          <description>Oral dose of matching placebo for BMS-986142 was administered daily for 12 weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Open globe injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rheumatoid arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Endometrial adenocarcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 21.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="14" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="75"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="73"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="73"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="75"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period &lt;=60 days from submitting for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Bristol-Myers Squibb Study Director</name_or_title>
      <organization>Bristol-Myers Squibb Study Director</organization>
      <phone>Please email</phone>
      <email>clinical.trials@bms.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

